What is Allermi?

Allermi is a custom-compounded, prescription nasal spray containing multiple FDA-approved ingredients that work synergistically to address the symptoms of allergic and non-allergic rhinitis — congestion, anterior and posterior rhinorrhea, pruritus, and sneeze.

Allermi is prescribed to qualifying patients via our telemedicine platform and is shipped directly from our licensed, accredited compounding pharmacies to the patient’s doorstep.

We offer ongoing support to each patient - including individualized formula adjustments where needed - via our telemedicine platform, MyAllermi, at no extra cost.

Which patients is Allermi indicated for?

Allermi is indicated for patients with allergic and non-allergic rhinitis. The patients who benefit most from Allermi have a history of moderate to severe rhinitis. Patients who cite congestion as their primary symptom do particularly well with Allermi, along with patients who have a history of nasal polyps, sinusitis or rhinitis medicamentosa.

Which active ingredients does Allermi contain?

We prescribe custom combinations of 2-4 of the following active ingredients within the respective listed dose ranges. We offer over 70 combination of these ingredients:

• Triamcinolone (anti-inflammatory corticosteroid) 0.055%-0.11%
• Azelastine (antihistamine) 0.137%
• Ipratropium (anticholinergic/anti-discharge) 0.015%-0.09%
• Oxymetazoline (decongestant, micro-dose) 0.003125%-0.0125%

How does Allermi safely incorporate oxymetazoline for daily relief?

Oxymetazoline is included in certain Allermi formulations to address congestion and to enhance the efficacy of other therapeutic ingredients - this is especially helpful to patients with moderate to severe congestion, nasal polyposis, history of sinusitis, and/or prior sinus surgery. For milder symptoms without a presentation of congestion, we offer formulas without oxymetazoline.

<aside> 💡 **It is important to understand that we only use oxymetazoline within a well-studied set of parameters:

Reduced Dosage:** We use oxymetazoline at a micro-dosage of 0.003125%-0.0125% (.1ml per spray), which is 1/12th to 1/48th of the standard dosage of oxymetazioline in Afrin (0.05%, .3ml per spray) and its generic equivalents.

Combination with INCS: We always pair our micro-dosage of oxymetazoline with the intranasal corticosteroid (INCS), triamcinolone acetonide. This combination has been demonstrated to effectively treat congestion and inflammation without causing rhinitis medicamentosa or rebound congestion.

</aside>

Please review the supporting studies below:

• The effectiveness of oxymetazoline plus intranasal steroid in the treatment of chronic rhinitis: A randomised controlled trial
• Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis.